Patrick Henry Mcdonough
Dermatology • Dallas, TX
6162 E Mockingbird Ln, Suite 120
Dallas, TX 752142697
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
NPI assigned on April 9, 2012; this date does not establish years in practice.
-
Published CMS data list 6,491 Original Medicare Part B services in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Published rows only; this is not a quality measure.
-
Published Part B service records, 2024:
- 17003 — Destruction of precancer skin growth, 2-14 growths: 2,976 service units.
- 99213 — Established patient outpatient office visit: 1,022 service units.
- 17000 — Destruction of precancer skin growth, 1 growth: 759 service units.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Units differ by code; these are not visits or a measure of quality.
CPT® only copyright 2023 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2024). CPT notice
See all 24 records in the table · Guide: How to read Medicare Part B data
-
Published CMS data list 2,360 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Triamcinolone Acetonide — 517 prescription fills, including refills.
- Ketoconazole — 266 prescription fills, including refills.
- Betamethasone Dipropionate — 150 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 36 records in the table · Guide: How to read Medicare Part D prescriber data
-
More Medicare Part B services than 90% of clinicians listed under Dermatology in Dallas, TX (2024, 78 clinicians with data). Median for this group: 1,701. Middle half: 564 to 3,288.
More Medicare Part B services than 80% of clinicians listed under Dermatology in Texas (2024, 830 clinicians with data). Median for this group: 2,197. Middle half: 1,083 to 4,729.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 2,874 in 2020 to 6,491 in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020–2024.
Practice Location & Contact Primary Location
6162 E Mockingbird Ln
Suite 120
Dallas, TX 752142697
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026
Rutgers New Jersey Medical School
2012
What Public CMS Data Show
Dermatology: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare patients
1,244 people with Original Medicare in 2024
It gives a sense of how many people with Medicare this clinician treated that year.
Source: CMS, Medicare Physician & Other Practitioners – by Provider, 2024.
Medicare-allowed amount
About $367,077 in 2024
The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
Paid by Medicare
About $259,255 in 2024
The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
30-day fills
2,646 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$797,873 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $475.27 across 20 records.
By nature of payment
- Food and Beverage: $475.27 across 20 records.
Reporting-company totals (3 largest of 7)
- Galderma Laboratories, L.P.: $203.34 across 5 records.
- Sanofi and Genzyme US Companies: $171.58 across 9 records.
- Amgen Inc.: $30.71 across 2 records.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
14 years (graduated 2012)
CMS Doctors and Clinicians data list 2012 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026.
NPI first issued
2012
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians, CMS release of October 2, 2026; Medicare.gov, “Does your provider accept Medicare as full payment?”
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians, CMS release of October 2, 2026.
Enrolled in Medicare (PECOS)
Patrick Mcdonough has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Patrick Mcdonough as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Dallas and Texas
Billing and prescribing volume is not a quality rating.
Medicare Part B services
More Medicare Part B services than 90% of clinicians listed under Dermatology in Dallas, TX (2024, 78 clinicians with data). Median for this group: 1,701. Middle half: 564 to 3,288.
More Medicare Part B services than 80% of clinicians listed under Dermatology in Texas (2024, 830 clinicians with data). Median for this group: 2,197. Middle half: 1,083 to 4,729.
Medicare-allowed amount
A higher Medicare-allowed amount than 85% of clinicians listed under Dermatology in Dallas, TX (2024, 78 clinicians with data). Median for this group: $105,899. Middle half: $44,336 to $171,644.
A higher Medicare-allowed amount than 80% of clinicians listed under Dermatology in Texas (2024, 830 clinicians with data). Median for this group: $135,436. Middle half: $65,432 to $291,321.
Paid by Medicare
A higher Medicare payment amount than 85% of clinicians listed under Dermatology in Dallas, TX (2024, 78 clinicians with data). Median for this group: $70,803. Middle half: $30,231 to $120,351.
A higher Medicare payment amount than 80% of clinicians listed under Dermatology in Texas (2024, 830 clinicians with data). Median for this group: $95,793. Middle half: $45,476 to $209,429.
Medicare Part D prescriptions
More Part D prescriptions than 95% of clinicians listed under Dermatology in Dallas, TX (2024, 81 clinicians with data). Median for this group: 337. Middle half: 163 to 628.
More Part D prescriptions than 95% of clinicians listed under Dermatology in Texas (2024, 934 clinicians with data). Median for this group: 479. Middle half: 197 to 946.
Part D drug cost
A higher Part D drug cost than 95% of clinicians listed under Dermatology in Dallas, TX (2024, 81 clinicians with data). Median for this group: $27,927. Middle half: $3,708 to $132,103.
A higher Part D drug cost than 90% of clinicians listed under Dermatology in Texas (2024, 934 clinicians with data). Median for this group: $79,996. Middle half: $6,799 to $221,327.
109 active clinicians are listed under Dermatology with a practice address in Dallas, TX (1,195 in Texas).
Addresses are self-reported to NPPES and may be out of date.
Telehealth indicator in Dallas
8.3% of these 109 clinicians have the CMS telehealth indicator.
69.7% of these 109 clinicians are listed by CMS as accepting Medicare assignment.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services increased 126% from 2,874 in 2020 to 6,491 in 2024.
- 2020: 2,874
- 2021: 3,442
- 2022: 4,284
- 2023: 5,246
- 2024: 6,491
-
Medicare-allowed amount
Medicare-allowed amount increased 133% from $157,364 in 2020 to $367,077 in 2024.
- 2020: $157,364
- 2021: $186,782
- 2022: $233,768
- 2023: $288,737
- 2024: $367,077
-
Paid by Medicare
Paid by Medicare increased 141% from $107,551 in 2020 to $259,255 in 2024.
- 2020: $107,551
- 2021: $130,172
- 2022: $158,164
- 2023: $197,099
- 2024: $259,255
-
Medicare Part D prescriptions
Medicare Part D prescriptions increased 80% from 1,314 in 2020 to 2,360 in 2024.
- 2020: 1,314
- 2021: 1,679
- 2022: 1,722
- 2023: 1,935
- 2024: 2,360
-
30-day fills
30-day fills increased 93% from 1,370 in 2020 to 2,646 in 2024.
- 2020: 1,370
- 2021: 1,798
- 2022: 1,896
- 2023: 2,134
- 2024: 2,646
-
Part D drug cost
Part D drug cost increased 1685% from $44,702 in 2020 to $797,873 in 2024.
- 2020: $44,702
- 2021: $312,626
- 2022: $358,434
- 2023: $564,466
- 2024: $797,873
-
Industry payments (Open Payments)
Industry payments (Open Payments) went from $205.68 in 2021 to $475.27 in 2025.
- 2021: $205.68
- 2022: $297.09
- 2023: $115.10
- 2024: $650.17
- 2025: $475.27
Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS release of October 2, 2026, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo · Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 – December 31, 2025): 20 records totaling $475.27.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Galderma Laboratories, L.P. |
Food and Beverage
In-kind items and services
|
NEMLUVIO | General | $149.24 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $26.67 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $26.44 |
| Galderma Laboratories, L.P. |
Food and Beverage
In-kind items and services
|
NEMLUVIO | General | $24.90 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $22.23 |
| LEO Pharma Inc. |
Food and Beverage
In-kind items and services
|
ADBRY | General | $19.78 |
| Botanix SB Inc |
Food and Beverage
In-kind items and services
|
SOFDRA | General | $19.77 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $17.81 |
| Galderma Laboratories, L.P. |
Food and Beverage
In-kind items and services
|
NEMLUVIO | General | $17.50 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $17.39 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $16.78 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $16.75 |
| Journey Medical Corporation |
Food and Beverage
In-kind items and services
|
— | General | $16.55 |
| Amgen Inc. |
Food and Beverage
In-kind items and services
|
Otezla | General | $15.89 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $15.33 |
| Amgen Inc. |
Food and Beverage
In-kind items and services
|
OTEZLA | General | $14.82 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $13.54 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $12.18 |
| Galderma Laboratories, L.P. |
Food and Beverage
In-kind items and services
|
NEMLUVIO | General | $9.06 |
| Galderma Laboratories, L.P. |
Food and Beverage
In-kind items and services
|
NEMLUVIO | General | $2.64 |
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016–2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2017–2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
17003
Destruction of precancer skin growth, 2-14 growths
|
2,976 | 470 | $11.51 | $6.96 |
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
1,022 | 725 | $151.37 | $94.34 |
|
17000
Destruction of precancer skin growth, 1 growth
|
759 | 604 | $133.71 | $64.06 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
300 | 218 | $221.66 | $133.79 |
|
11102
Biopsy of related skin growth, first growth
|
293 | 259 | $202.95 | $104.09 |
|
99203
New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
|
278 | 278 | $220.23 | $115.23 |
|
17004
Destruction of precancer skin growth, 15 or more growths
|
149 | 105 | $311.44 | $173.80 |
|
99212
Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
|
105 | 97 | $92.04 | $58.59 |
|
99204
New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
|
91 | 91 | $334.32 | $170.64 |
|
99202
New patient office or other outpatient visit with straightforward medical decision making, if using time, 15 minutes or more
|
70 | 70 | $155.59 | $73.88 |
|
17110
Destruction of skin growth, 1-14 growths
|
64 | 56 | $227.07 | $118.28 |
|
11103
Biopsy of related skin growth, each additional growth
|
58 | 46 | $109.42 | $52.81 |
|
11104
Punch biopsy, first skin growth
|
48 | 44 | $255.20 | $130.72 |
|
J3301
Injection, triamcinolone acetonide, not otherwise specified, 10 mg
|
38 | 23 | $20.00 | $0.96 |
|
J9190
Injection, fluorouracil, 500 mg
|
38 | 18 | $20.00 | $2.87 |
|
96405
Administration of chemotherapy into growth, 1-7
|
32 | 14 | $168.22 | $80.07 |
|
G2211
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
|
28 | 19 | $44.64 | $17.18 |
|
10060
Simple or single drainage of skin abscess
|
24 | 23 | $243.82 | $133.60 |
|
11900
Injection into skin growth, 1-7 growths
|
24 | 19 | $111.24 | $53.66 |
|
12032
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm
|
24 | 24 | $625.10 | $312.43 |
|
17262
Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm
|
24 | 23 | $361.85 | $183.77 |
|
11603
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm
|
21 | 19 | $581.78 | $146.33 |
|
11402
Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm
|
13 | 12 | $345.07 | $104.77 |
|
13101
Complicated repair of wound of trunk, 2.6-7.5 cm
|
12 | 12 | $822.74 | $414.63 |
Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Triamcinolone Acetonide | Triamcinolone Acetonide | 517 | 14,040 | $4,119.23 | 347 |
| Ketoconazole | Ketoconazole | 266 | 8,140 | $3,642.11 | 129 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 150 | 3,921 | $6,695.67 | 96 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 141 | 4,005 | $3,406.12 | 76 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 123 | 3,195 | $6,419.35 | 85 |
| Prednisone | Prednisone | 105 | 1,482 | $398.02 | 59 |
| Clobetasol Propionate | Clobetasol Propionate | 101 | 3,008 | $3,559.16 | 57 |
| Mupirocin | Mupirocin | 100 | 2,182 | $749.70 | 78 |
| Gabapentin | Gabapentin | 66 | 2,438 | $1,340.05 | 29 |
| Clindamycin Phosphate | Clindamycin Phosphate | 63 | 1,845 | $1,452.86 | 29 |
| Metronidazole | Metronidazole | 57 | 1,833 | $3,036.65 | 40 |
| Minoxidil | Minoxidil | 55 | 4,782 | $515.95 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 1,945 | $633.26 | 24 |
| Valacyclovir | Valacyclovir Hcl | 42 | 1,073 | $1,283.83 | 22 |
| Humira(Cf) Pen | Adalimumab | 40 | 1,120 | $271,780.02 | — |
| Cephalexin | Cephalexin | 39 | 215 | $176.35 | 32 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 38 | 1,315 | $2,137.98 | — |
| Dupixent Syringe | Dupilumab | 36 | 1,008 | $131,913.82 | — |
| Fluocinonide | Fluocinonide | 31 | 900 | $856.54 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | 1,170 | $717.84 | — |
| Otezla | Apremilast | 31 | 950 | $150,374.23 | — |
| Dupixent Pen | Dupilumab | 31 | 840 | $115,413.33 | — |
| Ciclopirox | Ciclopirox | 30 | 670 | $950.83 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 854 | $145.56 | 14 |
| Azelaic Acid | Azelaic Acid | 22 | 640 | $2,290.67 | — |
(top 25 shown)
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
NUCC Taxonomy Code: 207N00000X
A dermatologist is trained to diagnose and treat pediatric and adult patients with benign and malignant disorders of the skin, mouth, external genitalia, hair and nails, as well as a number of sexually transmitted diseases. The dermatologist has had additional training and experience in the diagnosis and treatment of skin cancers, melanomas, moles and other tumors of the skin, the management of contact dermatitis and other allergic and nonallergic skin disorders, and in the recognition of the skin manifestations of systemic (including internal malignancy) and infectious diseases. Dermatologists have special training in dermatopathology and in the surgical techniques used in dermatology. They also have expertise in the management of cosmetic disorders of the skin such as hair loss and scars and the skin changes associated with aging.
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - DERMATOLOGY
I20160926000951
TX
0840587424
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Clinicians Sharing This Practice Address or Phone
Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.
Social Worker - Clinical
Licensed Clinical Social Worker
Career & Practice History
NPI enumerated April 09, 2012.
No changes to the name, practice address, taxonomy or NPI status in this record have been observed in the monthly NPPES data files from January 2017 to November 2026.
NPI Administrative Meta
Other Dermatology Specialists in Dallas
- Dr. George Wooming, MD
- Dr. Kaveh Nezafati, MD
- Dr. Kelly Warren, MD
- Dr. Bahir Chamseddin, MD
- Aya Alame
- Dr. Khang Nguyen, MD
More public profiles in Texas
Directory navigation, in NPI number order.
- Elissa Dorsett, DPT Physical Therapist · Arlington
- Hannah Reed Dentist - General Practice · Whitehouse
- Ian Furlong, DDS Dentist - General Practice · San Antonio
- Huong Cook Nurse Anesthetist, Certified Registered · Lubbock
- Mackenzie Kelly, DPT Physical Therapist · Georgetown
- Karla Acevedo, AGACNP Nurse Practitioner - Acute Care · El Paso
- Eniola Buzombo, DNP, FNP-BC Nurse Practitioner - Family · Bellaire
- Garret Rupert, CRNA Nurse Anesthetist, Certified Registered · Dallas
- Joshua Bear, DDS Dentist - General Practice · Lake Jackson
- Kristiana Mclarty, MD Obstetrics & Gynecology - Urogynecology and Reconstructive Pelvic Surgery · Houston
- Christopher White, DDS Dentist - General Practice · Dallas
- Barbara Karnkowska, DO Internal Medicine - Cardiovascular Disease · Galveston
Mailing Address
6162 E Mockingbird Ln, Ste. 120
Dallas, TX 752142697